BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19305043)

  • 1. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.
    Davidson SR; Weersink RA; Haider MA; Gertner MR; Bogaards A; Giewercer D; Scherz A; Sherar MD; Elhilali M; Chin JL; Trachtenberg J; Wilson BC
    Phys Med Biol; 2009 Apr; 54(8):2293-313. PubMed ID: 19305043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
    Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
    BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
    BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy.
    Aniola J; Selman SH; Lilge L; Keck R; Jankun J
    Int J Mol Med; 2003 Mar; 11(3):287-91. PubMed ID: 12579328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy.
    Jankun J; Lilge L; Douplik A; Keck RW; Pestka M; Szkudlarek M; Stevens PJ; Lee RJ; Selman SH
    J Urol; 2004 Aug; 172(2):739-43. PubMed ID: 15247773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
    BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation.
    Huang Z; Chen Q; Trncic N; LaRue SM; Brun PH; Wilson BC; Shapiro H; Hetzel FW
    Radiat Res; 2004 Jun; 161(6):723-31. PubMed ID: 15161347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractionated versus standard continuous light delivery in interstitial photodynamic therapy of dunning prostate carcinomas.
    Xiao Z; Halls S; Dickey D; Tulip J; Moore RB
    Clin Cancer Res; 2007 Dec; 13(24):7496-505. PubMed ID: 18094434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of interstitial Doppler optical coherence tomography for in vivo detection of microvascular changes during photodynamic therapy.
    Li H; Standish BA; Mariampillai A; Munce NR; Mao Y; Chiu S; Marcon NE; Wilson BC; Vitkin A; Yang VX
    Lasers Surg Med; 2006 Sep; 38(8):754-61. PubMed ID: 16927368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer.
    Moore CM; Nathan TR; Lees WR; Mosse CA; Freeman A; Emberton M; Bown SG
    Lasers Surg Med; 2006 Jun; 38(5):356-63. PubMed ID: 16392142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate.
    Selman SH; Albrecht D; Keck RW; Brennan P; Kondo S
    J Urol; 2001 May; 165(5):1795-801. PubMed ID: 11342978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
    Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
    Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
    Trachtenberg J; Bogaards A; Weersink RA; Haider MA; Evans A; McCluskey SA; Scherz A; Gertner MR; Yue C; Appu S; Aprikian A; Savard J; Wilson BC; Elhilali M
    J Urol; 2007 Nov; 178(5):1974-9; discussion 1979. PubMed ID: 17869307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial photodynamic therapy of the canine prostate using intra-arterial administration of photosensitizer and computerized pulsed light delivery.
    Xiao Z; Dickey D; Owen RJ; Tulip J; Moore R
    J Urol; 2007 Jul; 178(1):308-13. PubMed ID: 17499802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy in the canine prostate using motexafin lutetium.
    Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
    Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP).
    Preise D; Scherz A; Salomon Y
    Photochem Photobiol Sci; 2011 May; 10(5):681-8. PubMed ID: 21258718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
    Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M
    World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatments for localized prostate cancer.
    Marberger M; Carroll PR; Zelefsky MJ; Coleman JA; Hricak H; Scardino PT; Abenhaim LL
    Urology; 2008 Dec; 72(6 Suppl):S36-43. PubMed ID: 19095127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effects of radiotherapy and photodynamic therapy on an in vitro human prostate model.
    Colasanti A; Kisslinger A; Quarto M; Riccio P
    Acta Biochim Pol; 2004; 51(4):1039-46. PubMed ID: 15625575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study on light dosimetry variables for photodynamic therapy of Barrett's esophagus with high-grade dysplasia.
    Gill KR; Wolfsen HC; Preyer NW; Scott MV; Gross SA; Wallace MB; Jones LR
    Clin Cancer Res; 2009 Mar; 15(5):1830-6. PubMed ID: 19240171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.